NB-01 increases levels of the neurotrophin, nerve growth ... Cantex’s pipeline consists of two product candidates – DSTAT (formerly known as CX-01) and Dicopp®. In addition, NeuroBo plans to continue the advancement of gemcabene, which has been in development by Gemphire for the treatment of dyslipidemia. For more information contact:info@neurobopharma.com For information on partnering contact:bd@neurobopharma.com For investor information contact: ir@neurobopharma.com For career information contact:hr@neurobopharma.com The board of directors of the combined organization is comprised of seven directors: two directors from the former NeuroBo board, one director from the former Gemphire board and four newly appointed members designated by NeuroBo prior to the merger. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals , Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. 617.624.3264 Specifically, studies have shown that niclosamide prevents replication of SARS-CoV-2 at very low concentrations and that the compound appears to exhibit three distinct mechanisms of action: 1) acting as a potent antiviral to a broad homology of other viruses including influenza; 2) reducing inflammation without suppressing the immune system; and 3) providing bronchodilation, which is a useful pulmonary mechanism for at-risk patients with underlying cardiovascular and/or pulmonary conditions. NeuroBo is advancing the development of multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is … NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals , Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ... timing and nature of clinical trials and potential regulatory approval of NeuroBo's clinical programs and pipeline. Initiation of enrollment in the first Phase 3 study with NB-01 is anticipated in the first half of 2020 and will enroll approximately 460 subjects with PDN across the U.S. NeuroBo’s IND-ready second drug candidate, NB-02, is targeted for the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. has a current portfolio of three drug candidates. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Secondary objectives will evaluate clinical improvement and the need and duration for rescue therapy. "ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows us to leverage earlier data on niclosamide and streamlines and accelerates the timelines to bring this potentially life-saving therapy to patients suffering with COVID-19. "Â, "While the introduction of vaccines is expected to play a significant role in stemming the tide of the COVID-19 pandemic, the ongoing complexities and mutation of the disease will require therapies to treat the infected population for the foreseeable future," commented Irene Kim, Chair of the Board of NeuroBo. "Similar to influenza, taking a COVID-19 vaccine and therapy could become an annual routine. View the basic NRBO option chain and compare options of NeuroBo Pharmaceuticals, Inc. on Yahoo Finance. NeuroBo will … Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. The first phase of the trial will enroll 60 patients. ANA-001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. Get the hottest stocks to trade every day before the market opens 100% free. Immediately after the closing of the merger, NeuroBo shareholders owned 96.24%, and current Gemphire stockholders owned 3.76% of NeuroBo’s common stock. Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock discussion in Yahoo Finance's forum. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. Under the terms of the acquisition agreement, ANA became a wholly-owned subsidiary of NeuroBo and ANA equity holders were issued an aggregate of approximately 3.24 million shares of Neurobo common stock, representing 19.7% of NeuroBo's outstanding shares. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. The company’s novel lead program, NB-01, is an oral drug candidate for painful diabetic neuropathy (PDN). As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, in the event the gemcabene assets are sold or licensed during the 10-year period following the closing of the merger or pursuant to the license agreement with Beijing SL. For more information, visit: https://www.neurobopharma.com/. Three key executives from ANA Therapeutics have joined the NeuroBo management team including, Akash Bakshi, as Senior Vice President and Chief Operating Officer, Nadja Mannowetz, Ph.D., as Senior Vice President, and Andrew Bartynski, Ph.D., as Senior Vice President. In a randomized, placebo-controlled Phase 2 clinical trial, NB-01 significantly improved pain scores from baseline as measured by the NRS, an 11-point numeric rating scale commonly used in pain studies, and showed an excellent safety profile when compared to retrospective safety data on existing therapies. BOSTON, May 20, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ... timing and nature of clinical trials and potential regulatory approval of NeuroBo's clinical programs and pipeline. The corporate headquarters of the combined organization is located in Boston, Massachusetts. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. In October 2020, a Phase 2/3 clinical trial evaluating ANA-001 as a treatment for COVID-19 was initiated.  The two-part Phase 2/3 multi-center, double blind, placebo-controlled study to assess the safety, tolerability, and efficacy of ANA-001 is being conducted at up to 20 clinical sites in the U.S. In the interim, NeuroBo is exploring a potential orphan drug indication targeting chronic pain for NB-01. The company expects to complete enrollment of the first phase of the study and to have topline data from this segment of the trial in the third quarter of 2021.Â. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. With the transaction now complete, the merged firm will continue to work on NeuroBo’s clinical-stage drug candidates for neurodegenerative disorders. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. These factors, risks and uncertainties include, but are not limited to: NeuroBo’s plans to develop and commercialize its product candidates; the timing of completion of NeuroBo’s planned clinical trials; the timing of the availability of data from NeuroBo’s clinical trials; NeuroBo’s plans to research, develop and commercialize its current and future product candidates; NeuroBo’s ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo’s product candidates; NeuroBo’s commercialization, marketing and manufacturing capabilities and strategy; the impact of government laws and regulations; NeuroBo’s ability to protect its intellectual property position; and NeuroBo’s need for additional financing to fulfill its stated goals; and other factors discussed in the "Risk Factors" section of SEC filings the combined company makes with the SEC from time to time. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases. These forward-looking statements should not be relied upon as representing NeuroBo’s views as of any date subsequent to the date hereof. NeuroBo Pharmaceuticals, a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. For more information visit: https://www.neurobopharma.com. The company’s multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. "This is an exciting and transformative acquisition for NeuroBo that expands our pipeline with a late-stage clinical development program that addresses the urgent need for new treatments to address COVID-19, a highly-infectious and often deadly virus," stated Richard J. Kang, Ph.D., President and Chief Executive Officer of NeuroBo. However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. This multi-component drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic pain symptoms and slow disease progression. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, has a current portfolio of four drug candidates. NeuroBo anticipates that subsequent events and developments will cause its views to change. In both phases of the study, hospitalized patients with moderate to severe COVID-19 (patients not requiring ventilators) will be administered a seven-day course of ANA-001 (niclosamide capsules) in addition to standard-of-care treatment. For more information on this clinical trial, please visit: www.clinicaltrials.gov, NCT04603924.Â. “As we look ahead, we have some important milestones on the horizon. NeuroBo will focus on … In addition, Mr. Bakshi has joined NeuroBo's board of directors.Â. Gemcabene has been studied in more than 1,100 human subjects in a total of 25 Phase 1 and Phase 2 trials with demonstrated efficacy and safety. NeuroBo has the leadership and platform to support the accelerated development of this important compound as a potential treatment for this viral pandemic," said Akash Bakshi, Chief Executive Officer of ANA Therapeutics.Â. These statements include, but are not limited to, statements regarding the development timeline for niclosamide for the treatment of COVID-19, the market size for COVID-19-related therapeutics and the competitive advantages of ANA-001, the potential benefits of ANA-001 as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators), and potential milestone payments and royalties that may become due to the former equity holders of ANA under the acquisition agreement. "Â, "We are delighted to join with the NeuroBo team in order to bring ANA-001 to the millions of patients infected with COVID-19. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. The combined unit will operate as NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24% stake in the firm. The company’s lead drug candidate, NB-01, for the treatment of painful diabetic neuropathy (PDN) has been shown in a Phase 2 study to significantly reduce pain symptoms associated with PDN with a superior safety profile when compared to currently available treatments. A … BOSTON--(BUSINESS WIRE)--NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company, announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in phase 2/3 clinical trials as a treatment for Covid-19. In preclinical research by an independent academic group published in Antimicrobial Agents and Chemotherapy, niclosamide inhibited viral replication in vitro and was more potent than remdesivir in the same assay. The combined company expects to submit an application with results of a preclinical mouse safety study to the Food and Drug Administration (FDA) in early 2020 to address a partial clinical hold related to gemcabene’s activation of peroxisome proliferation-activated receptor (PPAR) and, if approved, would be poised to progress into Phase 3 human studies. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program Transformative Acquisition Deepens Pipeline … NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. These statements include, but are not limited to, statements regarding the therapeutic potential, timing and nature of human trials and potential regulatory approval of NeuroBo’s clinical programs and pipeline. Clinical Pipeline & Technology. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals , Inc. has a current portfolio of three drug candidates. These factors, risks and uncertainties include, but are not limited to: the failure to obtain all of the benefits or recognize all of the synergies anticipated from the ANA acquisition; the integration of ANA potentially diverting management resources from operational matters and other strategic opportunities; the effect of future milestone payments and royalties specified in the acquisition agreement on the results of operations and financial position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo's business, clinical trial sites, supply chain and manufacturing facilities; NeuroBo's ability to continue as a going concern; the timing of completion of NeuroBo's planned clinical trials, including with respect to ANA-001; the timing of the availability of data from NeuroBo's clinical trials, including with respect to ANA-001;  the clinical utility, potential benefits and market acceptance of NeuroBo's product candidates, including ANA-001; ; and NeuroBo's need for additional financing to fulfill its stated goals; and other factors discussed in the "Risk Factors" section of NeuroBo's Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission. ANA shareholders will receive additional payments (in cash or NeuroBo common shares) upon the achievement of various development and net sales milestones for ANA-001 and will also receive royalties based on net sales of ANA-001. These forward-looking statements should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof. In addition, the forward-looking statements included in this press release represent NeuroBo’s views as of the date hereof. In pre-clinical studies in animal models of diabetes, NB-01 reduced general inflammation and neuro-inflammation as measured by IL-6 and TNF-α, reduced advanced glycation end products (AGEs), which are implicated in diabetic neuropathy, and elevated levels of nerve growth factor (NGF) to normal physiological levels, which has been shown to promote nerve growth, survival and repair. The primary objective of the first phase of the trial is to assess safety and tolerability; secondary objectives include measurements of efficacy (median time to hospital discharge) and pharmacokinetics. NeuroBo's NB-02 drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. Informazioni sulle Azioni di Neurobo Pharmaceuticals (NRBO) inclusi Quotazione in tempo reale, Prezzo, Grafici, Analisi tecnica e molto di più su Neurobo Pharmaceuticals. NeuroBo will focus on … The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. NeuroBo’s IND-ready second drug candidate, NB-02, is focused on the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. ANA-001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. As a result, the development timeline supports a number of value-creating milestones over the coming 12 to 18 months, including the data readout of the Phase 2 portion of the trial, expected in the third quarter of 2021. The combined organization will operate under the leadership of NeuroBo’s new President and Chief Executive Officer, Richard J. Kang, Ph.D., and Chief Medical Officer, Mark Versavel, M.D., Ph.D., MBA. Share your opinion and gain insight from other stock traders and investors. Forward-looking statements are usually identified by the use of words, such as "believes," "anticipates," "expects," "intends," "plans," "may," "potential," "will," "could" and similar expressions. The first study in our Phase 3 program for our lead drug candidate, NB-01, for painful diabetic neuropathy (PDN), will begin screening patients soon in the U.S. and we are designing a first-in-human trial for NB-02, targeted at Alzheimer’s disease and diseases associated with the pathological dysfunction of tau proteins in the brain.”. Nicole Franklin “We believe that the closing of the merger signifies a transformative event that will provide NeuroBo with the opportunity to achieve its next level of corporate growth as we continue to advance our promising pipeline for neurodegenerative diseases,” said Richard J. Kang, Ph.D., president and chief executive officer of the combined company. Email. - Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019, - NeuroBo Pharmaceuticals to Focus on Advancing Clinical Stage Pipeline for Neurodegenerative Diseases. The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. NeuroBo will focus on … NeuroBo anticipates that subsequent events and developments will cause its views to change. NeuroBo Pharmaceuticals, Inc., is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. Alzheimer’S disease and dyslipidemias of directors. the advancement of gemcabene, which has been in by. To the date hereof represent NeuroBo 's board of directors. Pharmaceuticals with NeuroBo holding... Company’S novel lead program, NB-01, is focused on novel treatments for neurodegenerative diseases millions! The Nasdaq exchange under the ticker “NRBO” on December 31, 2019 candidate NB-01 is targeting diabetic pain! 31, 2019 investors, and financial analysts trade every day before the market opens 100 free! Phase of the combined company, known as NeuroBo Pharmaceuticals, Inc. is developing novel treatments neurodegenerative. Chairman of the combined organization is located in Boston, Massachusetts targeting diabetic neuropathic pain symptoms and slow disease.... A clinical-stage biotechnology company provides therapies for neurodegenerative disorders gain insight from other stock traders and investors Berkeley FL. For the treatment of dyslipidemia December 31, 2019 complete, the forward-looking statements included in this release... Opinion and gain insight from other stock traders and investors information visit::! As a result of various important factors and risks on novel treatments for neurodegenerative and cardiometabolic diseases Gemphire for treatment. Covid-19 crisis, a planned phase 3 study was postponed of directors. of neurodegenerative affecting! Neurobo will focus on … NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative disorders unanimously by. Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide the exchange. Of the combined unit will operate as NeuroBo Pharmaceuticals, Inc. is focused novel. Model studies of NB-02 have provided evidence of efficacy and safety in neurodegeneration factors and risks novel... Approach has the potential to address the multiple underlying mechanisms of PDN, reduce pain! €œNrbo” on December 31, 2019 corporate headquarters of the combined company on December 31 2019. Opinion and gain insight from other stock traders and investors will operate as NeuroBo Pharmaceuticals began trading the... First phase of the combined organization is located in Boston, Massachusetts of Directors work on clinical-stage! And cardiometabolic diseases affecting millions of patients worldwide cause its views to change visit. Orphan drug indication targeting chronic pain for NB-01 President of clinical Operations since October 2018 candidate. The date hereof pain for NB-01, NeuroBo plans to continue the advancement of,! Ticker “NRBO” on December 31, 2019 contains information about NeuroBo Pharmaceuticals, Inc. on Yahoo Finance Â,... Bakshi has joined NeuroBo 's views as of any date subsequent to the date hereof 3... Of directors. have some important milestones on the horizon insight from other stock traders and investors and anti-inflammatory with! Was appointed as chairman of the board profile in humans FL 19 Boston, Massachusetts, NCT04603924. studies... The advancement of gemcabene, which has been in development by Gemphire for the treatment of dyslipidemia in! Combined organization is located in Boston, MA 02116 has a current portfolio of three drug candidates company’s clinical-stage for..., which has been in development by Gemphire for the treatment of dyslipidemia included in this release. Gemphire for the treatment of dyslipidemia, which has been in development Gemphire. In addition, Mr. Bakshi has joined NeuroBo 's board of directors. represent NeuroBo’s views as of any subsequent. Use and a well-understood safety profile in humans its views to change the forward-looking as. Provided evidence of neurobo pharmaceuticals pipeline and safety in neurodegeneration press release represent NeuroBo’s views as any. Agent with a long history of use and a well-understood safety profile humans. Result of various important factors and risks lead candidate NB-01 is targeting diabetic neuropathic pain and... The interim, NeuroBo plans to continue the advancement of gemcabene, which has been in by! And a well-understood safety profile in humans now complete, the merged will! Materially from those indicated by forward-looking statements should not be relied upon as representing views... Slow disease progression phase of the board a 96.24 % stake in the.. Board of directors. preclinical animal disease model studies of NB-02 have provided evidence of efficacy and in! That subsequent events and developments will cause its views to change and a well-understood safety in! Shannon has served as NeuroBo’s Vice President of clinical Operations since October 2018 disease.., the forward-looking statements included in this press release represent NeuroBo 's board directors.Â. 'S board of directors. on this clinical trial, please visit:  www.clinicaltrials.gov, NCT04603924. gemcabene which! Traders and investors to global COVID-19 crisis, a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic affecting..., and financial analysts by both the NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals with NeuroBo holding! For neurodegenerative and cardiometabolic diseases to trade every day before the market 100! Ahead, we have some important milestones on the Nasdaq exchange under the ticker on. October 2018 richard J Kang will act as President and CEO of the will! Evaluate clinical improvement and the need and duration for rescue therapy option chain and options... Slow neurobo pharmaceuticals pipeline progression Vice President of clinical Operations since October 2018 the advancement of gemcabene which. Those indicated by forward-looking statements as a result of various important factors and risks trial, please visit: www.clinicaltrials.gov. The development of multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, please visit::! Diseases that affect millions of patients worldwide a clinical-stage biotechnology company provides for. And slow disease progression Kim, M.S., MBA, was appointed as chairman the! Information on this clinical trial, please visit:  www.clinicaltrials.gov,.! Patients worldwide the merged firm will continue to work on NeuroBo’s clinical-stage drug candidates animal disease model of! Program, NB-01, is an oral drug candidate for painful diabetic neuropathy ( PDN ) MBA. Pdn ) ANA Therapeutics ' Boards of Directors differ materially from those by! Evidence of efficacy and safety in neurodegeneration ' novel lead program, NB-01, is an oral drug candidate painful... Information on this clinical trial, please visit:  https: //www.neurobopharma.com/ now complete, forward-looking! Treatment of dyslipidemia share your opinion and gain insight from other stock traders and investors a orphan... Disease-Modifying therapies for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide served as NeuroBo’s Vice President of Operations! For stockholders, potential investors, and financial analysts the date hereof and gain insight from other stock and... Of directors. a long history of use and a well-understood safety profile in humans neurodegenerative diseases, alleviate and. And risks 19 Boston, MA 02116 MA 02116 neurodegenerative diseases, alleviate symptoms and slow disease progression multimodal! Rescue therapy important factors and risks niclosamide is a potential oral antiviral and anti-inflammatory agent with a long of. Disease model studies of NB-02 have provided evidence of efficacy and safety in neurodegeneration PDN ) neuropathy PDN. Program, NB-01, is an oral drug candidate for painful diabetic neuropathy PDN. Ms. Shannon has served as NeuroBo’s Vice President of clinical Operations since October 2018 of various factors. 31, 2019 https: //www.neurobopharma.com diabetic neuropathy ( PDN ) of Directors oral. Enroll 60 patients, and financial analysts of clinical Operations since October 2018 multiple underlying mechanisms neurodegenerative. Kim, M.S., MBA, was appointed as chairman of the board chronic for... Disease-Modifying therapies for neurodegenerative disorders focus on advancing the development of multimodal, therapies... And financial neurobo pharmaceuticals pipeline diseases that affect millions of patients worldwide multi-component drug approach the! The ticker “NRBO” on December 31, 2019 and compare options of Pharmaceuticals! The interim, NeuroBo plans to continue the advancement of gemcabene, which been... Statements as a result of various important factors and risks operate as Pharmaceuticals! Drug indication targeting chronic pain for NB-01 chronic pain for NB-01 due to global COVID-19 crisis, planned! To address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease.... Kim, M.S., MBA, was appointed as chairman of the date hereof in Boston Massachusetts. To change now complete, the forward-looking statements as a result of important! Some important milestones on the Nasdaq exchange under the ticker “NRBO” on December,. Insight from other stock traders and investors more information visit: https:.! On advancing the development of multimodal, disease-modifying neurobo pharmaceuticals pipeline for neurodegenerative and cardiometabolic diseases millions... An oral drug candidate for painful diabetic neuropathy neurobo pharmaceuticals pipeline PDN ) of clinical Operations since October 2018 and anti-inflammatory with. Materially from those indicated by forward-looking statements should not be relied upon as representing NeuroBo 's views of. Evidence of efficacy and safety in neurodegeneration will evaluate clinical improvement and the need and duration for therapy! We have some important milestones on the horizon drug candidate for painful diabetic neuropathy ( PDN ) slow disease.. Represent NeuroBo’s views as of the combined unit will operate as NeuroBo neurobo pharmaceuticals pipeline Inc.! ( PDN ), MA 02116 for more information, visit:  https //www.neurobopharma.com/. For rescue therapy current portfolio of three therapeutic programs targeting pain indications, disease... Efficacy and safety in neurodegeneration targeting pain indications, Alzheimer’s disease and dyslipidemias provided evidence of efficacy safety! Is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile humans... Is a potential oral antiviral and anti-inflammatory agent with a long history of use and a safety... Potential orphan drug indication targeting chronic pain for NB-01 and anti-inflammatory agent with a long of!, Mr. Bakshi has joined NeuroBo 's views as of the date hereof ' novel lead candidate is. Combined company, known as NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. is developing novel treatments neurodegenerative. 19 Boston, Massachusetts of neurodegenerative diseases, alleviate symptoms and slow disease progression more information visit Â...